Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection

Authors

Pablo Tebas, Washington University School of Medicine in St. Louis
Kevin Yarasheski, Washington University School of Medicine in St. Louis
Keith Henry, Regions HospitalFollow
Sherri Claxton, Washington University School of Medicine in St. Louis
E. Kane, Regions Hospital
B. Bordenave Regions Hospital
Michael Klebert, Washington University School of Medicine in St. Louis
William G. Powderly, Washington University School of Medicine in St. Louis

Journal

AIDS Research and Human Retroviruses

Publication Date

2004

Volume

20

Issue

6

Inclusive Pages

589-594

Document Type

Open Access Publication

DOI

10.1089/0889222041217374

Rights and Permissions

Pablo Tebas, Kevin Yarasheski, Keith Henry, Sherri Claxton, E. Kane, B. Bordenave, Michael Klebert, and William G. Powderly. AIDS Research and Human Retroviruses. June 2004, 20(6): 589-594. doi:10.1089/0889222041217374. This is a copy of an article published in AIDS research and human retroviruses © 2004 [copyright Mary Ann Liebert, Inc.]; AIDS research and human retroviruses is available online at: http://online.liebertpub.com.

Recommended Citation

Tebas, Pablo; Yarasheski, Kevin; Henry, Keith; Claxton, Sherri; Kane, E.; Bordenave, B. Regions Hospital; Klebert, Michael; and Powderly, William G., "Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection." AIDS Research and Human Retroviruses. 20, 6. 589-594. (2004).
https://digitalcommons.wustl.edu/open_access_pubs/3126